Literature DB >> 1389316

Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children.

A Gimesi1, M Eibl, R Koós, P Somló, E Magyarossy, G Kardos, E Fazekas, M Schmidt, J Borsi, D Schuler.   

Abstract

60 children with acute lymphoblastic leukemia were sequentially randomized at the time of diagnosis: Immunoglobulin (Endobulin, Immuno) was administered intravenously to 30 patients at a dose 100 mg/kg/week during the first 3 months, followed by 2 x 200 mg/kg/month immunoglobulin during the 4., 5., 6. months. No immunoglobulin was administered to the control patients. We studied the effect of immunoglobulin prophylaxis on the number of days with fever, number of cases with bacteriologically proved infections, length and frequency of antibiotic therapy. Our data confirm the efficacy of immunoglobulin prophylaxis during the intensive phase of leukemia therapy in children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389316

Source DB:  PubMed          Journal:  Acta Paediatr Hung        ISSN: 0231-441X


  3 in total

1.  Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective.

Authors:  Patrick Van Winkle; Raoul Burchette; Raymond Kim; Rukmani Raghunathan; Naveen Qureshi
Journal:  Perm J       Date:  2018

Review 2.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  Hypogammaglobulinemia in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.

Authors:  Cassandra S Lange; April Rahrig; Sandra K Althouse; Robert P Nelson; Sandeep Batra
Journal:  J Adolesc Young Adult Oncol       Date:  2020-07-13       Impact factor: 1.757

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.